HGF/c-MET信号通路抑制剂在抗胰腺癌中的研究进展

doi:10.3760/cma.j.issn.1673-422X.2017.04.017

摘要/Abstract

摘要： 胰腺癌是恶性程度较高的肿瘤之一。靶向治疗日渐成为胰腺癌治疗的重要组成部分。研究证实肝细胞生长因子及其受体（HGF/c-MET）信号通路在胰腺癌发生、发展过程中起重要作用，通过抑制该条信号通路能够起到显著的抗胰腺癌作用。因此，HGF/c-MET靶向抑制剂的研究为胰腺癌的治疗开辟了一条新的途径。

关键词: 肝细胞生长因子, 胰腺肿瘤, 原癌基因蛋白质c-met

Abstract: Pancreatic cancer is one of the most malignant tumors. Targeted therapy has become an important part of the treatment of pancreatic cancer. The signaling pathways such as hepatocyte growth factor/c-MET (HGF/c-MET) signaling pathway, inhibition of which may exerts an antitumor effect, play extremely important roles in the occurrence and development of pancreatic cancer. Therefore, the research of HGF/c-MET targeted inhibitors opens up a new avenue for treatment of pancreatic cancer.

Key words: Hepatocyte growth factor, Pancreatic neoplasms, Proto-oncogene proteins c-met

乔银标,杨波. HGF/c-MET信号通路抑制剂在抗胰腺癌中的研究进展[J]. 国际肿瘤学杂志, 2017, 44(4): 304-306.

Qiao Yinbiao, Yang Bo. Research progress of HGF/c-MET signaling pathway inhibitors in antipancreatic cancer[J]. Journal of International Oncology, 2017, 44(4): 304-306.

参考文献

［1］ Nones K, Waddell N, Song S, et al. Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and Met signaling［J］. Int J Cancer, 2014, 135(5): 1110-1118. DOI: 10.1002/ijc.28765. ［2］ Pothula SP, Xu ZH, Goldstein D, et al. Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer［J］. Br J Cancer, 2016, 114(3): 269-280. DOI: 10.1038/bjc.2015.478. ［3］ Delitto D, Vertes-George E, Hughes SJ, et al. c-Met signaling in the development of tumorigenesis and chemoresistance: potential applications in pancreatic cancer［J］. World J Gastroenterol, 2014, 20(26): 8458-8470. DOI: 10.3748/wjg.v20.i26.8458. ［4］ Huang C, Qiu ZJ, Wang LW, et al. A novel FoxM1-Caveolin signaling pathway promotes pancreatic cancer invasion and metastasis［J］. Cancer Res, 2012, 72(3): 655-665. DOI: 10.1158/0008-5472.CAN-11-3102. ［5］ Bao B, Wang Z, Ali S, et al. Over-expression of FoxM1 leads to epithelial-mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells［J］. J Cell Biochem, 2011, 112(9): 2296-2306. DOI: 10.1002/jcb.23150. ［6］ Cui J, Xia T, Xie D, et al. HGF/c-Met and FOXM1 form a positive feedback loop and render pancreatic cancer cells resistance to Met inhibition and aggressive phenotypes［J］. Oncogene, 2016, 35(36): 4708-4718. DOI: 10.1038/onc.2016.14. ［7］ Yu H, Lee H, Herrmann A, et al. Revisiting STAT3 signalling in cancer: new and unexpected biological functions［J］. Nat Rev Cancer, 2014, 14(11): 736-746. DOI: 10.1038/nrc3818. ［8］ Patel MB, Pothula SP, Xu Z, et al. The role of the hepatocyte growth factor/c-MET pathway in pancreatic stellate cell-endothelial cell interactions: antiangiogenic implications in pancreatic cancer［J］. Carcinogenesis, 2014, 35(8): 1891-1900. DOI: 10.1093/carcin/bgu122. ［9］ Gherardi E, Birchmeier W, Birchmeier C, et al. Targeting Met in cancer: rationale and progress［J］. Nat Rev Cancer, 2012, 12(2): 89-103. DOI: 10.1038/nrc3205. ［10］ Garajova I, Giovannetti E, Biasco G, et al. c-Met as a target for personalized therapy［J］. Transl Oncogenomics, 2015, 7(Suppl 1): 13-31. DOI: 10.4137/TOG.S30534. ［11］ Chen HM, Tsai CH, Hung WC. Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling［J］. Oncotarget, 2015, 6(17): 14940-14952. DOI: 10.18632/oncotarget.3613. ［12］ Grullich C. Cabozantinib: a Met, RET, and VEGFR2 tyrosine kinase inhibitor［J］. Recent Results Cancer Res, 2014, 201: 207-214. DOI: 10.1007/978-3-642-54490-3_12. ［13］ Hage C, Rausch V, Giese N, et al. The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer［J］. Cell Death Dis, 2013, 4(5): e627-e627. DOI: 10.1038/cddis.2013.158. ［14］ Zhen DB, Griffith KA, Ruch JM, et al. A phase Ⅰ trial of cabozantinib and gemcitabine in advanced pancreatic cancer［J］. Invest New Drugs, 2016, 34(6): 733-739. DOI: 10.1007/s10637-016-0376-1. ［15］ You WK, Sennino B, Williamson CW, et al. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer［J］. Cancer Res, 2011, 71(14): 4758-4768. DOI: 10.1158/0008-5472.CAN-10-2527. ［16］ Liu XD, Wang Q, Yang GJ, et al. A novel kinase inhibitor, INCB28060, blocks c-MET-Dependent signaling, neoplastic activities, and Cross-Talk with EGFR and HER3［J］. Clin Cancer Res, 2011, 17(22): 7127-7138. DOI: 10.1158/1078-0432.CCR-11-1157. ［17］ Brandes F, Schmidt K, Wagner C, et al. Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model［J］. BMC Cancer, 2015, 15: 71. DOI: 10.1186/s12885-015-1064-9.

[1]	张洁, 范玲, 李杰, 温华, 苏媛媛, 路宁, 张明鑫. 原发性胰腺淋巴瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 316-320.
[2]	魁国菊, 黄江宾, 张文华, 杨立民. 区域淋巴结大小对胰头腺癌术后复发的影响[J]. 国际肿瘤学杂志, 2023, 50(10): 608-613.
[3]	严志颖, 毛逸锋, 朱颖蔚, 徐克群. 癌相关成纤维细胞的异质性在靶向胰腺癌治疗中的角色[J]. 国际肿瘤学杂志, 2021, 48(5): 308-312.
[4]	中国医师协会放射肿瘤治疗医师分会. 胰腺癌立体定向放疗(放射外科)指南[J]. 国际肿瘤学杂志, 2021, 48(11): 643-648.
[5]	钟扬, 何苗, 刘志, 陈建宇, 张光年, 秦龙, 李婷, 李建水. 麦冬皂苷D联合沉默环氧合酶-2基因对人胰腺癌BxPC-3细胞增殖、迁移和侵袭的影响[J]. 国际肿瘤学杂志, 2021, 48(10): 583-590.
[6]	李珂珂, 孔盼盼, 易超, 王喜艳, 晏冬. 淋巴样增强因子-1在胰腺导管腺癌中的表达及对预后的影响[J]. 国际肿瘤学杂志, 2021, 48(10): 608-613.
[7]	陈晓旭, 于洋, 张天雪. 基于免疫相关lncRNA建立胰腺癌预后风险评估模型[J]. 国际肿瘤学杂志, 2020, 47(8): 472-479.
[8]	田春方, 沙丹. 锌指蛋白与消化系统肿瘤[J]. 国际肿瘤学杂志, 2020, 47(2): 115-118.
[9]	纪周新, 贺德. 微生物群与胰腺癌[J]. 国际肿瘤学杂志, 2020, 47(1): 46-50.
[10]	靳小倩,韩春,王澜. 胰腺实性假乳头状瘤变异型快速进展一例[J]. 国际肿瘤学杂志, 2019, 46(4): 255-256.
[11]	李庆贺, 刘慧纯, 张家耀, 李伟. miR-200b-3p下调VEGFA调控胰腺癌细胞增殖、侵袭、迁移和凋亡的分子机制研究#br#[J]. 国际肿瘤学杂志, 2019, 46(11): 649-656.
[12]	李智,许静凯,张博. 长非编码RNA在肿瘤中的作用机制[J]. 国际肿瘤学杂志, 2018, 45(4): 220-222.
[13]	李志坚，贺德. 液体活检在胰腺癌中的研究进展[J]. 国际肿瘤学杂志, 2018, 45(3): 180-182.
[14]	梁碧玉，何伟明，何小艺，丁元林，于海兵. 糖尿病及降糖药物与胰腺癌[J]. 国际肿瘤学杂志, 2018, 45(3): 183-186.
[15]	陈罗军,李娜,田景媛,许斌,宋启斌. 非功能性胰腺神经内分泌癌的预后因素分析[J]. 国际肿瘤学杂志, 2018, 45(12): 721-726.